It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Adult T-cell leukemia/lymphoma (ATL) is caused by human T-cell leukemia virus type 1 (HTLV-1). In addition to HTLV-1 bZIP factor (HBZ), a leukemogenic antisense transcript of HTLV-1, abnormalities of genes involved in TCR-NF-κB signaling, such as CARD11, are detected in about 90% of patients. Utilizing mice expressing CD4+ T cell-specific CARD11(E626K) and/or CD4+ T cell-specific HBZ, namely CARD11(E626K)CD4-Cre mice, HBZ transgenic (Tg) mice, and CARD11(E626K)CD4-Cre;HBZ Tg double transgenic mice, we clarify these genes’ pathogenetic effects. CARD11(E626K)CD4-Cre and HBZ Tg mice exhibit lymphocytic invasion to many organs, including the lungs, and double transgenic mice develop lymphoproliferative disease and increase CD4+ T cells in vivo. CARD11(E626K) and HBZ cooperatively activate the non-canonical NF-κB pathway, IRF4 targets, BATF3/IRF4/HBZ transcriptional network, MYC targets, and E2F targets. Most KEGG and HALLMARK gene sets enriched in acute-type ATL are also enriched in double transgenic mice, indicating that these genes cooperatively contribute to ATL development.
The oncogenic ability of mutant CARD11 (E626K), one of most frequently mutated genes in adult T-cell leukemia and its cooperative effect with HBZ expression, using the CD4 promoter-driven HBZ transgenic mouse model, is investigated.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Miyazaki, Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, Miyazaki, Japan (GRID:grid.410849.0) (ISNI:0000 0001 0657 3887)
2 National Cancer Center Research Institute, Division of Molecular Oncology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385)
3 Chordia Therapeutics, Fujisawa, Japan (GRID:grid.272242.3)
4 Kumamoto University, Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749)
5 Miyazaki Prefectural Miyazaki Hospital, Department of Anatomic Pathology, Miyazaki, Japan (GRID:grid.274841.c)
6 Hokkaido University, Department of Immunology, Graduate School of Pharmaceutical Sciences, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)
7 Kyoto University, Department of Pathology and Tumor Biology, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
8 Tokushima Bunri University, Faculty of Pharmaceutical Sciences at Kagawa Campus, Kagawa, Japan (GRID:grid.412769.f) (ISNI:0000 0001 0672 0015)
9 Chordia Therapeutics, Fujisawa, Japan (GRID:grid.412769.f)
10 National Cancer Center Research Institute, Division of Molecular Oncology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385); Keio University School of Medicine, Division of Hematology, Department of Medicine, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)